## Nigel Jepson

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12152888/publications.pdf

Version: 2024-02-01

1040056 794594 28 366 9 19 citations h-index g-index papers 29 29 29 666 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Impact of the Complexity of Bifurcation Lesions Treated With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2014, 7, 1266-1276.	2.9	153
2	Prognostic Significance of Peri-procedural Myocardial Infarction in the Era of High Sensitivity Troponin: A Validation of the Joint ACCF/AHA/ESC/WHF Universal Definition of Type 4a Myocardial Infarction with High Sensitivity Troponin T. Heart Lung and Circulation, 2015, 24, 673-681.	0.4	21
3	Patent Foramen Ovale Influences the Presentation of Decompression Illness in SCUBA Divers. Heart Lung and Circulation, 2015, 24, 26-31.	0.4	19
4	Drug-eluting Balloon Versus Second Generation Drug Eluting Stents in the Treatment of In-stent Restenosis: A Systematic Review and Meta-analysis. Heart Lung and Circulation, 2016, 25, 1184-1194.	0.4	17
5	Coronary stent technology: a narrative review. Medical Journal of Australia, 2016, 205, 277-281.	1.7	16
6	3D Printing for Cardiovascular Applications: From End-to-End Processes to Emerging Developments. Annals of Biomedical Engineering, 2021, 49, 1598-1618.	2.5	15
7	Periprocedural myocardial infarction is associated with increased mortality in patients with coronary artery bifurcation lesions after implantation of a drugâ€eluting stent. Catheterization and Cardiovascular Interventions, 2015, 85, 696-705.	1.7	14
8	Topological Optimization of Auxetic Coronary Stents Considering Hemodynamics. Frontiers in Bioengineering and Biotechnology, 2021, 9, 728914.	4.1	12
9	Threeâ€year clinical outcomes of patients treated with everolimusâ€eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial. Catheterization and Cardiovascular Interventions, 2019, 93, E1-E7.	1.7	11
10	Cardiac Complications in Patients Hospitalised With COVID-19 in Australia. Heart Lung and Circulation, 2021, 30, 1834-1840.	0.4	10
11	Optimal duration of dual antiplatelet therapy following drug-eluting stents implantation: A meta-analysis of 7 randomised controlled trials. International Journal of Cardiology, 2015, 201, 578-580.	1.7	8
12	Balloon Aortic Valvuloplasty in the Transcatheter Valve Era: Single Centre Indications and Early Safety Data in a High Risk Population. Heart Lung and Circulation, 2018, 27, 595-600.	0.4	8
13	A multi-objective optimization of stent geometries. Journal of Biomechanics, 2021, 125, 110575.	2.1	8
14	Asia Pacific consensus document on coronary bifurcation interventions. EuroIntervention, 2020, 16, e706-e714.	3.2	8
15	Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers. Journal of Invasive Cardiology, 2016, 28, 316-22.	0.4	8
16	One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. EuroIntervention, 2016, 12, 1255-1262.	3.2	7
17	Design and Rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial. Cardiovascular Drugs and Therapy, 2016, 30, 169-175.	2.6	6
18	Rotational Atherectomy Combined with Drug Coated-Balloons for in-Stent Restenosis. Cardiovascular Revascularization Medicine, 2019, 20, 559-562.	0.8	5

#	Article	IF	CITATIONS
19	Association of hypertension with mortality in patients hospitalised with COVID-19. Open Heart, 2021, 8, e001853.	2.3	4
20	Peri-procedural myocardial infarction following percutaneous coronary intervention as defined by the Universal Definition predicts increased mortality at 2years. International Journal of Cardiology, 2015, 199, 96-98.	1.7	3
21	Performance and Safety of Transfemoral TAVI With SAPIEN XT in Australian Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: SOLACE–AUÂTrial. Heart Lung and Circulation, 2020, 29, 1839-1846.	0.4	3
22	Letter to the Editor: CSANZ Consensus Guidelines for Interventional Cardiology Services Delivery During COVID-19 Pandemic in Australia and New Zealand. Heart Lung and Circulation, 2020, 29, 1260-1261.	0.4	3
23	South Pacific Underwater Medicine Society guidelines for cardiovascular risk assessment of divers. Diving and Hyperbaric Medicine, 2020, 50, 273-277.	0.5	3
24	"Full bioresorbable jacket†Alternative to very long segment metallic stenting in a young patient with diffuse coronary artery disease. International Journal of Cardiology, 2016, 223, 361-363.	1.7	2
25	Percutaneous Thrombin Injection: An Alternative Therapy for latrogenic Carotid Artery Pseudoaneurysms. EJVES Vascular Forum, 2022, 55, 52-55.	0.4	1
26	Bioresorbable scaffoldâ€"the holy grail of percutaneous coronary intervention: fact or myth?. Journal of Thoracic Disease, 2016, 8, E589-E592.	1.4	0
27	Phaeochromocytoma presenting with labile blood pressures following coronary artery bypass grafting. Journal of Cardiac Surgery, 2016, 31, 721-724.	0.7	O
28	Coronary stent technology: a narrative review. Medical Journal of Australia, 2017, 206, 413-414.	1.7	O